Journal Home
Search for

Volume 161, Issue 2, Pages 151-158 (September 2005)


View previous. 11 of 18 View next.

THY-1 induction is associated with up-regulation of fibronectin and thrombospondin-1 in human ovarian cancer

Harindra R. Abeysinghe, Li Qiong Li, Nedra L. Guckert, Jay Reeder, Nancy WangCorresponding Author Informationemail address

Received 16 March 2004; received in revised form 21 January 2005; accepted 1 February 2005.

Abstract 

We recently identified THY-1 as a putative tumor suppressor gene for human ovarian cancer. To understand the carcinogenic role of THY-1, and its downstream effects on cancer cells, a THY-1 inducible system was established in the human ovarian cancer cell line SKOV-3 based on the tetracycline (tet) regulating system. To establish an inducible system for Thy-1 expression, two plasmids, pUHD172-1neo and pTEP4mThy-1, which are neomycin and hygromycin resistant were co-transfected into the ovarian carcinoma cell line, SKOV-3. The inducibility of Thy-1 expression in the SKOV-3 cell line by doxycycline (dox) was determined by northern blot analysis, immunocytochemistry, and flow cytometry. A time course study revealed that Thy-1 expression is induced 3 hours post dox exposure. Expression was reversible such that 12 hours post the removal of dox almost no Thy-1 could be detected. Furthermore, 2 genes, Fibronectin (FN) and Thrombospondin (TSP-1) involved in cellular differentiation and the regulation of tumor angiogenesis, respectively, were found to be up-regulated upon THY-1 induction. In contrast, the gene SPARC was found to be independent of Thy-1 expression. This study supports the hypothesis that THY-1 plays a critical role in regulating downstream genes associated with the regulation of ovarian tumor growth and cellular differentiation.

Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 608, Rochester, New York 14642

Corresponding Author InformationCorresponding author. Tel: 585-275-6597; fax: 585-273-3360.

PII: S0165-4608(05)00115-9

doi:10.1016/j.cancergencyto.2005.02.014


View previous. 11 of 18 View next.